Biotome – R&D Tax Incentive customer story

 

Biotome develops next generation antibody diagnostic tools.

Having access to this R&D Tax Incentive is very helpful. It reduces the risks, or the demands, of capital raising. It’s been a very smooth process for us to work with AusIndustry.
— Dr Samuel Lundin, CEO, Biotome.

Company Profile

Company: Biotome Pty Ltd

Sector: Biotechnology

Location: Perth, WA

Profile: Biotome Pty Ltd is a Perth-based biotechnology company that develops next generation antibody diagnostic tools. Their solutions combine modern technology with precision immunology to address the problems of traditional serology tests.

Biotechnology companies often conduct R&D that includes clinical trials to demonstrate efficacy of new products and processes, such as drugs or diagnostic tools. Companies who conduct R&D that involves clinical trials may be able to rely on the R&DTI clinical trials determination to register their core R&D activities under the program. The determination is designed to help biotechnology companies like Biotome access the R&DTI with greater certainty and less effort.

Was this page helpful?

Thanks for sharing your feedback with us.

Why not?

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.